Guidance
12 Sources of evidence considered by the Committee
The diagnostics assessment report was prepared by Kleijnen Systematic Reviews Ltd in collaboration with Erasmus University Rotterdam and Maastricht University.
-
Westwood ME, Joore MA, Whiting P et al. Epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: a systematic review and cost-effectiveness analysis. (January 2013)
Registered stakeholders
The following organisations accepted the invitation to participate in this assessment as registered stakeholders. They were invited to attend the scoping workshop and to comment on the diagnostics assessment report and the diagnostics consultation document.
Professional/specialist and patient/carer groups:
-
All Wales Molecular Genetics Lab
-
AstraZeneca
-
Boehringer Ingelheim Limited
-
Bristol Genetics Laboratory
-
British Thoracic Oncology Group (BTOG)
-
Cancer Research UK
-
Coventry and Warwickshire Pathology Services
-
Department of Molecular Haematology, Oxford University Hospitals Trust
-
Edinburgh Cancer Centre
-
European Molecular Genetics Quality Network
-
Guy's and St. Thomas' NHS Foundation Trust
-
Leeds Teaching Hospital
-
The Lothian University Hospitals
-
NCRI Clinical Studies Group/Royal College of Physicians/Royal College of Radiologists/Joint Collegiate Council on Oncology/Association of Cancer Physicians
-
New Gene Ltd
-
NHS Grampian
-
NHS Greater Glasgow and Clyde
-
Royal Devon and Exeter NHS Trust
-
Sheffield Diagnostics Genetics Service
-
St James's Hospital
-
St Mary's Hospital
-
UCL Advanced Diagnostics
-
UK NEQAS (Edinburgh)
-
United Lincolnshire Hospitals NHS Trust
-
University College London Hospital and MRC Clinical Trials Unit
-
University Hospitals Birmingham NHS